A series of new dihydropyrimidinone-semicarbazone hybrids were successfully synthesised by integrating regioselective multicomponent reaction with the pharmacophore hybridization approach. All the synthesised compounds were evaluated for their hLig1 inhibition potency and most of them were found to be good to moderately active. Out of the tested derivatives, compound 6f showed selective anti-proliferative activity against HepG2 cells in a dose-dependent manner with an IC50 value 10.07±1.2. It also reduced cell survival at ≤20 μM concentration. Further, analysis of treated HepG2 cells lysate by western blot assay showed increased γH2AX levels and upregulation of p53, leading to apoptosis. Insilico docking results explain binding modes of compound 6f to DNA-binding domain of hLig1 enzyme thereby preventing its nick sealing activity. In addition, the favourable pharmacokinetic properties suggest that this new class of hLig1 inhibitors could be promising leads for further drug development.